A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Public ClinicalTrials.gov record NCT07728383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Study identification
- NCT ID
- NCT07728383
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- Placebo liquid emulsion formulation Drug
- Semaglutide 6 mg liquid emulsion formulation Drug
- Wegovy® (semaglutide) Tablet Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 16, 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
- Last update posted
- Jul 26, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Institute of Minnesota | Minneapolis | Minnesota | 55402 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Obesity & Overweight trials
Other public records listing Obesity & Overweight. Sorted by last update posted; newest first. Not a recommendation.
- NCT07787533: Digital Resistance Training for Midlife Women Using GLP-1 Not yet recruiting
- NCT07778524: Alpelisib Challenge Test (ACT) Not yet recruiting
- NCT07776678: Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity Recruiting
- NCT07509502: Optimizing Lifestyles Through Increased Vegetable-rich Eating Pilot Study Active, not recruiting
- NCT07747805: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD Not yet recruiting
- NCT07743567: Gestational Response, Outcomes, and Weight After GLP-1 Use Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07728383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2026 · Synced Jul 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07728383 live on ClinicalTrials.gov.